Life Tech Expifectamine 293 Transfection Kit Tender - 105738763

Procurement Summary

Country: USA

Summary: Life Tech Expifectamine 293 Transfection Kit (Ambis 2228842)

Deadline: 23 Aug 2024

Posting Date: 14 Aug 2024

Other Information

Notice Type: Tender

TOT Ref.No.: 105738763

Document Ref. No.: RFQ-NIAID-24-2228842

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: Refer Document

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_detailsLogin to see details

Tender Details

Description
This notice is a Combined Synopsis/Solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 “Streamlined Procedures for Evaluation and solicitation for commercial Items, ” as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-24-2228842 and the solicitation is issued as a Request for Quotes (RFQ).
This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2024-05, May 22, 2024.
The North American Industry Classification System (NAICS) code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing, with a size standard of 1250 employees. The requirement is being competed with a brand name restriction, and without a small business set-aside.
The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the following Brand Name Supplies:
1. ExpiFectamine 293 Transfection Kit, 10L, Product #: A14525, qty 8 each
2. Shipping and Handling, qty 1 each
The Vaccine Research Center (VRC) is to provide a mechanistic basis for
developing preventive vaccines against HIV, malaria, tuberculosis, SARS-CoV2 and therapeutic vaccines against cancer. The project aims to harness the Expi Transfection System for advanced vaccine research, focusing on accelerating the development and optimization of novel vaccine candidates. This system is integral for the production of high-yield, high-quality recombinant proteins and viral vectors, essential components in vaccine development. Thermo Fisher Sc...
Active Contract Opportunity

Notice ID : RFQ-NIAID-24-2228842

Related Notice

Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Sub-tier : NATIONAL INSTITUTES OF HEALTH

Office: NATIONAL INSTITUTES OF HEALTH NIAID

General Information

Contract Opportunity Type: Combined Synopsis/Solicitation (Original)

All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA

Original Published Date: Aug 13, 2024 05:38 pm EDT

Original Date Offers Due: Aug 23, 2024 11:00 am EDT

Inactive Policy: 15 days after date offers due

Original Inactive Date: Sep 07, 2024

Initiative: None
Classification

Original Set Aside:

Product Service Code: 6550 - IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS

NAICS Code: 325413 - In-Vitro Diagnostic Substance Manufacturing
Place of Performance: Bethesda, MD 20892 USA

Documents

 Tender Notice

2_Terms_and_Conditions_RFQ-NIAID-24-2228842_FAR_52.pdf